IQVIA Biotech launches in Asia Pacific & Japan, dedicated to emerging biopharma industry

New Delhi: IQVIA has announced the Japan and Asia Pacific (JAPAC) expansion of  IQVIA Biotech, a tailored approach to delivering integrated clinical and commercial solutions for biotech and emerging biopharma companies.

IQVIA Biotech teams use lean operating procedures and scientific specialization to deliver flexible solutions, powered by IQVIA’s technology enabled services, that can help innovative companies reach their drug development and commercialization milestones.

“Biotech companies are fueling rapid development of biologics, drugs, and vaccines, and when they succeed, we all succeed,” said Richard Staub, president, Research & Development Solutions at IQVIA. “By launching IQVIA Biotech in JAPAC, we can support the aspirations of biotech customers with agile solutions and resources dedicated to supporting smaller companies.”

Launched in North America and Europe in early 2019, IQVIA Biotech was designed in response to the needs of biotech customers for transparent and fit-for-purpose clinical processes with dedicated, therapeutically aligned partners. Since its launch, IQVIA Biotech has initiated hundreds of new trials for biotech companies, including COVID-19 trials.

With specialized expertise in oncology, central nervous system disorders, dermatology, and cardiovascular and rare diseases, IQVIA Biotech has regional headquarters in Singapore and offices in 15 countries across the region. The dedicated IQVIA Biotech teams in JAPAC are equipped to meet the unique needs of biotech customers by creating intelligent connections across the drug development process.

“Biotech companies have increasing global aspirations, and demand is also growing from global emerging customers for delivery in this region,” said Dr Senthil Sockalingam, head, IQVIA Biotech, JAPAC and chief medical officer, APAC. “IQVIA Biotech allows us to offer customers a truly seamless experience fully aligned with flexible and tailored integrated solutions delivered by specialized teams.”